Protein arginine methyltransferase 3 promotes glycolysis and hepatocellular carcinoma growth by enhancing arginine methylation of lactate dehydrogenase A

Abstract

Background Protein arginine methylation has emerged a pivotal role in cancer progression. However, the role of protein arginine methyltransferase 3 (PRMT3) in hepatocellular carcinoma (HCC) remains unknown. Methods The expression pattern of PRMT3 in HCC was analysed using quantitative real‐time‐polymerase chain reaction (qRT‐PCR), Western blotting and immunohistochemistry assays. Loss‐ and gain‐of‐function experiments were carried out to determine the oncogenic role of PRMT3 in HCC. Glucose consumption and lactate production assays, seahorse bioscience, mass spectrometry, co‐immunoprecipitation, metabonomic analysis and site‐specific mutation experiments were used to explore the underlying molecular mechanisms. Furthermore, a xenograft mouse model was established to investigate the effects of PRMT3 and its inhibitor, SGC707, treatment on tumour growth in vivo. Results The expression of PRMT3 was significantly upregulated in HCC, with high expression of which correlated with poor prognosis. PRMT3 knockdown led to the decrease in proliferation, glycolysis of HCC cells and tumour growth, whilst its overexpression showed opposite results. The catalytic activity of PRMT3 was important in mediating these biological processes. Mechanistically, our data showed that PRMT3 interacted with and mediated asymmetric dimethylarginine (ADMA) modification of lactate dehydrogenase A (LDHA) at arginine 112 (R112). Compared with LDHA‐wild‐type (LDHA‐WT) cells, LDHA‐R112K‐mutant‐expressing HCC cells exhibited a decrease in lactate dehydrogenase (LDH) activity, HCC cell glycolysis and proliferation. Furthermore, the administration of SGC707, a selective inhibitor of PRMT3, disrupted the PRMT3‐mediated LDHA methylation and abolished PRMT3‐induced HCC glycolysis and tumour growth. Conclusions Our results suggested a novel oncogenic role of PRMT3 in HCC, and it could be a promising therapeutic target for HCC by linking post‐translational modification and cancer metabolism.

Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications

“…In CRC, METTL3 mediates the m6A modification of HK2 and SLC2A1 mRNA, which leads to their stabilization and activates the glycolytic pathway [ 115 ]. Furthermore, glycolytic enzymes such as LDHA and PKM2 can be methylated by methyltransferase, which can also change their activity [ 116 , 117 ]. Hence, methylation plays an important role in regulating the glycolytic metabolism of cancer cells.…”

PRMT3 drives glioblastoma progression by enhancing HIF1A and glycolytic metabolism

“…SGC707, a bioavailable drug, is a selective inhibitor of PRMT3 and potently inhibits its methyltransferase activity in cells [44,57]. SGC707 has been reported to have an anti-tumor effect in other cancer model [47,[57][58][59]. Herein, we provide the first evidence that SGC707 has an anticancer effect in GBM.…”

Cell adhesion molecule BVES functions as a suppressor of tumor cells extrusion in hepatocellular carcinoma metastasis

“…As we previously described [ 17 ], the tissues were paraformaldehyde-fixed and paraffin-embedded, and the SP Detection System Kits were used for immunohistochemistry staining (ZSGB-BIO, cat# SP-9000) according to the instructions. The intensity of staining was divided into 0 (negative), 1 (weak), 2 (medium) and 3 (strong).…”